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Our discovery of a novel cytoplasmic domain in HEp-2 cells recognized by the autoimmune serum
of a patient led us on a journey into the world of microRNAs (miRNA). Our journey began with
the identification and cloning of the novel glycine (G)–tryptophan (W)-rich protein, GW182,
and its close interaction with the miRNA-binding protein, argonaute2 (Ago2). Discovering the
important relevance of GW182 with miRNA function was the igniting force that steered us toward
understanding the role of miRNAs in autoimmunity and the innate immune response. This brief
paper highlights our journey and key findings.
The Discovery of GW Bodies
In the early 2000s, using the serum from a patient with motor and sensory polyneuropathy, we
identified a 182-kDa autoantigen that localized to a novel cytoplasmic domain in HEp-2 cells
(1). The cytoplasmic domain was distinct from other cytoplasmic organelles including lysosomes,
endosomes, and the Golgi complex. The number and size of the foci were cell-cycle dependent
with the largest and most abundant occurring during late S and G2 phase. Based on the predicted
molecular size and the unique distribution of glycine (G) and tryptophan (W) repeats throughout
the protein, the antigen was designated as GW182. The cytoplasmic entities/foci were thus termed
GW182-protein-rich bodies or GW bodies (GWBs, Figure 1A).
The functional role of GW182 was explored with immunoprecipitation studies. We used human
prototype anti-GW182 serum to identify a 100-kDa protein that co-immunoprecipitated with
GW182 in HeLa cell lysate. The protein was identified, via mass spectroscopy, as Ago2. Ago2
is a member of the Argonaute family of proteins which bind miRNA and are involved in post-
transcriptional gene silencing processes. Interestingly, we also identified autoantibodies to Ago2 as
previously described anti-Su antibodies (2). Ago2, the only catalytic Ago protein, binds miRNA such
that it is in position/configuration to recognize target mRNAs. Once the complex of Ago2–miRNA
binds to the 30UTRof targetmRNA,GW182 is recruited to initiate translational repression and target
mRNA degradation (3). Our discovery of GW182 as a key facilitator of Ago2–miRNA-mediated
post-transcriptional gene regulation piqued our interest as to the functional role of miRNA in
autoimmunity.
miRNAs Associated with GW Bodies
MicroRNAs are now defined components of the large population of non-coding regulatory RNAs
known to be transcribed in mammalian cells. With over an estimated 1000 miRNAs, their regulation
of gene expression is diverse (4). For instance, a common mechanism of miRNA involves a single
miRNA modestly repressing several different mRNAs in a common biologic process. Moreover,
multiple miRNAs can cooperatively regulate individual components within a single molecular
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FIGURE 1 | Glycine (G)–Tryptophan (W) bodies (GWBs) and microRNA
regulation in innate immune response. (A) Using a human prototype serum,
we identified a novel cytoplasmic domain (green) in HEp-2 anti-nuclear antibody
assay; nuclei are counterstained blue with DAPI. We termed this GWB due to
the presence of a 182-kDa glycine–tryptophan repeat-rich protein, GW182.
Formation of GWBs is cell-cycle dependent with absence at G1 phase and an
increase in size and number in late S/G2 phase. Increase in GWBs is seen in
monocytes after LPS-stimulation. (B) Our proposed model of microbial
tolerance and cross-tolerance regulated by miRNAs via targeting of
Myddosome complex. Endotoxin tolerance in THP-1 cells primed and
challenged with LPS involves the binding of LPS to the LPS-binding protein
which is complexed to MD-2, CD14, and TLR-4. Binding results in formation of
the Myddosome complex (MyD88, IRAK4, and IRAK 1/2), which then recruits
TRAF6. These events lead to transcription of pro-inflammatory cytokines as well
as miR-146a via NF-κB nuclear translocation. Upregulated miR-146a abrogates
TNF-α transcription by blocking IRAK1/2 and TRAF6 mRNA expression even
when challenged with high-dose LPS. This leads to a state of endotoxin
tolerance. This phenomenon is observed with other microbial
components – PGN and flagellin. However, PGN-mediated tolerance occurs
through binding of PGN to TLR2, transcriptional activation of CREB, and a
subsequent rapid induction of miR-132/-212. miR-132/-212 then inhibits IRAK4
leading to tolerance to PGN. Interestingly, upregulation of miR-132/-212 was
also observed with cross-tolerance when cells were primed with PGN and
subsequently challenged with TLR5-ligand, flagellin.
pathway. Intron-encoded miRNAs have been shown to regulate
flanking mRNA expression and then modulate the same pro-
cess (4).
MicroRNA expression is initiated by the transcription of a
primary miRNA transcript in the nucleus (5). Cleavage of the
transcript to a pre-miRNA by Drosha–DGCR8 microprocessor
complex is followed by transport into the cytoplasm via exportin-
5. Continual processing by protein Dicer generates the mature
miRNA, which is about 20–23 nucleotides in length. Mature
miRNA are loaded on Ago2, which allows for the right config-
uration to recognize potential mRNA targets in the cytoplasm.
Translational control occurs when miRNA–Ago complexed with
a target mRNA recruit GW182 to form the core miRNA-induced-
silencing complex (miRISC). GW182 mediates deadenylation
by interacting with the poly-A-binding proteins and recruit-
ing deadenylases. Once the poly-A-tail is shortened, mRNA is
degraded.
MicroRNA, Ago2, and GW182 are key components of GWBs.
Other components include RNA decay factors and mRNA.
Autoantibodies have been identified to components of GWB are
predominantly directed to Ago2 and GW182 (6). As a matter of
fact, autoantibodies have been detected in several autoimmune
diseases including ataxia and motor and sensory neuropathy, Sjö-
gren’s syndrome, systemic lupus erythematosus, primary biliary
cirrhosis, and rheumatoid arthritis (RA) (7).
GW Bodies in Biological Responses and as
Marker of miRNA Activity
Our initial studies to examine the potential role of GWBs in a bio-
logical response involved stimulating human monocytes cell line
(THP-1) with lipopolysaccharide (LPS). With LPS-stimulation,
we noted a time-dependent increase in the number and size of
GWBs with the highest number seen after 8 h LPS-stimulation as
compared to unstimulated controls (8). We then evaluated a vari-
ety of chemokines and pro- and anti-inflammatory cytokines, for
their ability to induce an increase in GWBs. Stimulation with pro-
inflammatory cytokines, in particular TNF-α, resulted in a sig-
nificant increase in GWBs as compared to unstimulated controls.
When tested on peripheral blood monocytes (PBMCs) from a
healthy donor, similar findings were observed. Thus, the increase
in size and number ofGWBs could be used as amarker formiRNA
activity (8). About the same time, it was shown that LPS could
stimulate the production of miR-146a, miR-132, and miR-155 in
THP-1 cells. Thus, we proceeded to use THP-1 cells as a model to
study miRNA expression and its relationship to GWB (8).
miRNAs in Inflammatory Disease States
With the discovery of increased miRNA activity in pro-
inflammatory states, we next turned our attention to miRNA
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expression in RA, a TNF-α-mediated autoimmune disease.
The expression of several miRNAs was evaluated in PBMCs of
RA patients and compared to healthy and disease controls. A
statistically significant increase in miR-146a, miR-132, miR-155,
and miR-16 mRNA levels was seen in PBMCs from RA patients.
Furthermore, high levels of miR-146a and miR-16 correlated with
active disease as defined by CRP and ESR values. Subsequently,
the aberrant expression of miRNAs in RA has been underscored
in several studies (5, 7). Overexpression of miR-221/222, miR-
323-3p, and miR-203 has been noted in synovial fibroblasts in
the arthritic phenotype of RA. Underexpression of miR-34a,
miR-124a, and miR-23b was found to be related to increased
synovial fibroblasts proliferation and their resistance to apoptosis
(9). However, miR-146a is the only miRNA consistently reported
elevated in other independent laboratories ranging from articular
tissue to different blood cells of RA patients [reviewed in Ref. (5,
7)]. Together, these studies demonstrate the role of miR-146a in
RA and suggested a pathogenic role in autoimmune diseases.
miR-146a Regulates Via NF-κB-Dependent
Pathway
From the above discussed studies, miR-146a stood out as a
potential key mediator of innate immune dysfunction with
potential biological relevance in RA. It was demonstrated that
LPS-induced miR-146a expression is nuclear factor-kappa B (NF-
κB)-dependent. mRNA targets include IL-1 receptor-associated
kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6),
which are key components of the Toll-like receptor (TLR)-4 sig-
naling pathways. We took on the task of further defining the
function of miR-146a in the innate immune response. First, we
stimulated THP-1 cells with increasing doses of LPS and observed
a dose- and time-dependent increase in TNF-α protein expres-
sion, peaking at 4–6 h. We then noted that MyD88 pathway
adaptors, TRAF6 and IRAK1, mRNA expression, which also went
up after LPS-stimulation with a profile similar to that of TNF-α.
The expression ofmiR-146a was consistent with previous findings
that miR-146a negatively regulates TRAF6 and IRAK1. The unex-
pected surprise, however, was the continued increase in miR-146a
levels, reaching 30- to 100-folds by 72 h, even when the mRNA
levels of TRAF6 and IRAK1 already returned to normal levels.
miR-146a and Endotoxin-Induced
Tolerance
Sustained high levels ofmiR-146a in the presence of LPSwere pos-
tulated to play a dominant functional role in endotoxin tolerance.
Endotoxin tolerance is the refractory response of neutrophils and
macrophages to subsequent LPS-stimulation, leading to reduced
production of pro-inflammatory cytokines. To explore this, THP-
1 monocytes were primed with 0, 10, 100, or 1000 ng/ml of LPS
for 18 h and then challenged them with 1000 ng/ml of LPS for
5 h. A 90% decrease in TNF-α protein and mRNA expression was
seen with 10 ng/ml of LPS priming and a complete abrogation
of TNF-α expression was seen at 100 and 1000 ng/ml of LPS. A
concomitant decrease in TRAF6 and IRAK1 mRNA levels was
also detected. In contrast, miR-146a mRNA levels continued to
increase proportional to level of LPS. To demonstrate that miR-
146a was critical for endotoxin-induce tolerance, two experiments
were performed. Transfection ofmiR-146amimic intoTHP-1 cells
induced a comparable endotoxin tolerance state with statistically
significant reduction in cytokinesTNF-α, IL-1β, and IL-6 produc-
tion when challenged with high-dose LPS, effectively mimicking
LPS priming. One the other hand, transfection with a miR-146a
inhibitor abolished LPS-tolerance even in THP-1 cells primed
with low-dose LPS.
From these studies, the following molecular model was
proposed to explain miR-146a mediation of LPS-tolerance
(Figure 1B). LPS binds TLR-4–CD14 and another accessory pro-
teinMD-2. The LPS-initiated TLR-4 signaling cascade leads to the
formation of the Myddosome complex (which includes MyD88,
IRAK4, IRAK1/2), which then recruits TRAF6. This chain of
events triggers activation and translocation of NF-κB and results
in the transcription of immune-responsive genes and cytokines
such as TNF-α as well as miR-146a. In essence, in our system,
activation of the pathway leads to early TNF-α expression, then
a steady increase of miR-146a which block IRAK1 and TRAF6
mRNA expression even when challenged with high-dose LPS,
leading to the state of LPS-tolerance.
Since IL-1 signaling shares the same MyD88-dependent path-
way, the relevance of miR-146a to IL-1β signaling was further
examined (10). Unwarranted overproduction of cytokines, such
as IL-1β, can cause severe pathological complications and thus
elaborate mechanisms are needed to regulate its onset and ter-
mination. The capability of IL-1β to induce tolerance and cross-
tolerance against various inflammatory ligands was investigated.
IL-1β-stimulated THP-1 monocytes showed a gradual increase of
miR-146a, reaching 15-fold expression by 24 h. miR-146a upregu-
lation induced tolerance toward subsequent challenges of IL-1β,
LPS, peptidoglycan (PGN), Pam, and flagellin in THP-1 cells.
The induction of tolerance was dependent on IL-1β-priming dose
and associated increase of miR-146a expression. Thus, miR-146a
seems to operate as a negative regulatory feedback mechanism
to prevent the destructive consequences of uncontrolled cytokine
or chemokine production during the IL-1β and TLR signaling
cascade. Given that the miR-146a response by IL-1β was observed
in primary mouse macrophage as well as in human monocytes,
miR-146a is now demonstrated to play an important physiological
role in the regulation of IL-1β signaling (10).
In support of our findings, several in vivo studies using miR-
146a null mouse model have established miR-146a as a nega-
tive regulator of inflammation and a key player in hematopoi-
etic malignancies. Lack of miR-146a in these mice leads to
hyperresponsiveness of macrophages to endotoxin and an exag-
gerated inflammatory response in endotoxin-challenged mice
(11, 12).
TLR2/TLR5-Induced miR-132/-212
Functions in Tolerance and
Cross-Tolerance
miR-146a may not be the only miRNA involved in microbial
tolerance. When we primed THP-1 cells with PGN, similar to
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LPS-stimulation, exposure of THP-1 cells to PGN, led to an
early increase in TNF-α protein expression and a decline
within 24 h. When cells were primed with PGN and subse-
quently challenged with PGN, tolerance was observed. We deter-
mined that unlike LPS-induced tolerance, PGN-induced tol-
erance occurs through rapid induction of miR-132/-212 via
CREB transcription factor. Induction of miR-132/-212 leads to
inhibition of IRAK4 mRNA expression. Furthermore, instead
of TLR-4-mediated activation, activation is mediated through
TLR2. Cross-tolerance was observed when cells primed with
PGN were subsequently challenged with TLR5-ligand, flag-
ellin. Collectively, these data demonstrate that miRNAs tar-
get components of the Myddosome complex in order to
induce tolerance/cross-tolerance (13). It should be noted that
in an earlier study using miR-132/-212 knockout mice, loss of
the miRNA cluster did not apparently impact LPS-induction
of specific plasma cytokine levels, including TNF-α (14).
This is not inconsistent with our findings in THP-1 mono-
cytes that the role of miR-132/-212 in tolerance and cross-
tolerance was primarily induced from TLR2 ligand PGN or
PAM (13).
Our studies of miRNAs in innate immunity and tolerance,
demonstrates that there are a subset of miRNAs with dominant
functions (9). A dominant miRNA is best defined as a miRNA
whose presence or absence dictates cellular function. When
induced, it can affect many target genes in a dose-dependent
manner. miR-146a is the prototype in innate immune response.
In adaptive immunity, miR-182 has been proposed to act in
this same dominant manner. In vivo and in vitro studies show
that miR-182 induction by IL-2 promotes clonal expansion of
T helper cells through Foxo1 regulation. Blocking miR-182 can
lead to improvement of arthritis in the ovalbumin-induced arthri-
tis model. Dominant miRNAs if clinically relevant may provide
therapeutic targets for autoimmune diseases (15).
The Voyage Continues
In summary, our observation, over 10 years ago, of a novel cyto-
plasmic entity introduced us to an important concept in gene
regulation. The identification of miRNAs in autoimmune disease
provided us with the foreground to explore their function. Our
studies have provided important mechanistic insight into their
regulation of the innate immune response. It is exciting to think
that we may have new targets to assist in diagnosing, monitoring,
and possibly treating diseases that are impacted by the dysregula-
tion of innate immunity. Continual exploration and collaborative
efforts to explore how these master regulators are altered during
inflammatory disease processes may be the key to uncovering the
etiology of immune-mediated diseases.
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